Skip to content
Screener

Alkermes ALKS Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$78.5M+90.4%
AbbVie logo
AbbVieABBV
$919M+173%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$2.99M-89.8%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$7M+141%
LBR
LB Pharmaceuticals IncLBRX
$93.83M

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Employee taxes paid related to net share settlement of equity awards(24,538)(30,459)
Payment for the repurchase of ordinary shares(27,696)
Principal payments of long-term debt(6,625)
Cash flows provided by financing activities1,491,7241,152
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(608,247)230,053
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period1,119,776291,146
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period$511,529$521,199
SUPPLEMENTAL CASH FLOW DISCLOSURE:

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's financing cash flow?
Alkermes (ALKS) reported financing cash flow of $17.21M in Q2 2026.
How has Alkermes's financing cash flow changed year-over-year?
Alkermes's financing cash flow increased by 4148.1% year-over-year, from $405K to $17.21M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Alkermes's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude